Clinical Trials Logo

Amphetamine Addiction clinical trials

View clinical trials related to Amphetamine Addiction.

Filter by:
  • None
  • Page 1

NCT ID: NCT03318081 Recruiting - Clinical trials for Amphetamine Addiction

The Application of Cognitive Rehabilitation Therapy for Amphetamine-type Stimulants Addiction

Start date: October 20, 2017
Phase: N/A
Study type: Interventional

The computerized cognitive rehabilitation therapy will be used to treat amphetamine-type stimulant (ATS) addiction.

NCT ID: NCT03221283 Recruiting - Clinical trials for Amphetamine Addiction

The Application of Music Therapy in Female Amphetamine Use Disorder

Start date: November 30, 2017
Phase: N/A
Study type: Interventional

The group music therapy will be used to treat female amphetamine-type stimulant (ATS) addiction

NCT ID: NCT02952196 Suspended - Clinical trials for Amphetamine Addiction

Cannabioids as a New Intervention for Amphetamine Dependence

Start date: March 2018
Phase: Phase 2
Study type: Interventional

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). It has been demonstarted that cannabidioids can have physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly cannabinoids have been shown to be potentially helpful in treating addiction, due to their effects on various neuronal circuits involved in this disorder. The investigators overall hypothesis is that cannabinoids are an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

NCT ID: NCT02950376 Not yet recruiting - Clinical trials for Amphetamine Addiction

The Novel Addiction Assessment Study in Synthetic Drugs Addiction

Start date: December 2016
Phase: N/A
Study type: Observational

The purpose of this research is to develop an objective assessment based on the virtual reality techniques which is used for evaluate addiction severity.

NCT ID: NCT02836756 Not yet recruiting - Clinical trials for Amphetamine Addiction

Cannabidiol as a New Intervention for Amphetamine Dependence

Start date: October 2016
Phase: Phase 2
Study type: Interventional

Addiction to amphetamine is characterized by alternating phases of intoxication and short abstinence, followed by recurrent drug-craving episodes which result in distress and relapse. Addiction involves a number of neurotransmission systems, including the endocannabinoid system (ECBS). Cannabidiol (CBD), the second most abundant component of cannabis, is known for its broad spectrum of physiological, anxiolytic and neuroprotective properties. It has been shown to have multiple therapeutic properties for treating anxiety, schizophrenia and interestingly CBD has been shown to be potentially helpful in treating addiction, due to its effects on various neuronal circuits involved in this disorder. Our overall hypothesis is that CBD is an interesting pharmacological contender to decrease amphetamine craving and treat amphetamine addiction.

NCT ID: NCT02713815 Recruiting - Clinical trials for Amphetamine Addiction

Novel Intervention for Amphetamine-type Stimulants Addiction

Start date: July 2016
Phase: N/A
Study type: Interventional

The motivational-cognitive psychotherapy and repetitive transcranial magnetic stimulation (rTMS) will be used to treat amphetamine-type stimulant (ATS) addiction.

NCT ID: NCT02285556 Completed - Clinical trials for Amphetamine Addiction

The Diagnostic Assessment and Intervention Study of Amphetamine Type Stimulus

Start date: March 2012
Phase: N/A
Study type: Interventional

The purpose of this research is to inspire new medical ideas using brain image technology for the treatment of Amphetamine Type Stimulus addition, at the same time lowing the addition damage.

NCT ID: NCT00713479 Completed - Clinical trials for Amphetamine Addiction

An Assessment of the Safety of Varenicline in Methamphetamine-dependent Volunteers

Start date: July 2008
Phase: Phase 1
Study type: Interventional

More people worldwide use amphetamine-type stimulants than any illicit drug besides cannabis, and methamphetamine (MA) abuse and dependence is the fastest growing drug problem in the United States. Much work remains in identifying an effective pharmacotherapy for MA dependence. The neurobiological actions produced by MA involve dopamine (DA), serotonin, and norepinephrine, but also include alterations to cholinergic neurotransmitter systems. Candidate compounds that target acetylcholine (ACh) are attractive options for development that have not received adequate attention. Varenicline is a drug that increases the release of DA in the brain and it is logical to assume that it would to some extent compensate for the reduction in these neurotransmitters that occurs in MA withdrawal. Current research has linked certain genes that are related to neurotransmitters with drug abuse and memory impairment (e.g., A1 allele for the D2 dopamine receptor and catechol-O-methyltransferase). We will take blood samples and test for these genes in order to relate the findings to brain function. This is a double-blind, placebo-controlled, within-subjects study to determine the safety and tolerability of MA in MA-dependent volunteers treated with varenicline and placebo.